Disease Burden and Impact of Certolizumab Pegol Treatment on Workplace and Household Productivity Across Working Age Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis Patients

Arthur F. Kavanaugh¹, Philip J. Mease², Oana Purcaru³ and Désirée van der Heijde⁴, ¹Division of Rheumatology, Allergy, and Immunology, UC San Diego School of Medicine, La Jolla, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³208 Bath Road, UCB Pharma, Slough, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: axial spondyloarthritis, certolizumab pegol, Psoriatic arthritis, Rheumatoid arthritis (RA) and work

Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), can impact significantly on patients’ (pts’) ability to perform work-related tasks in both paid employment and the household.^1,2 Previous results show improvements in work and household productivity with certolizumab pegol (CZP) in pts with established RA,^3,4 PsA⁵ and axSpA.⁶ We examined the comparative economic burden of RA, PsA and axSpA and the impact of CZP on productivity after 1 year (yr) in pts of working age.

Methods: Baseline (BL) and 1 yr data from: RA: PREDICT (NCT01255761),³ RAPID 1 (NCT00152386),⁴ RAPID 2 (BL data only, NCT00160602);⁴ PsA: RAPID-PsA (NCT01087788);⁵ axSpA: RAPID-axSpA (NCT01087762).⁶ Pts received CZP loading dose (400 mg at Weeks [Wks] 0, 2, 4), followed by 200 mg Q2W+MTX (RA), or 200 mg Q2W or 400 mg Q4W (PsA/axSpA). The arthritis-specific Work Productivity Survey (WPS),⁷ administered Q4W from BL, assessed the impact of disease on workplace and household productivity. Disease burden at BL and WPS responses (LOCF imputation) over 52 wks (RA) and 48 wks (PsA/axSpA), in CZP-treated pts stratified by age and employment status, are summarized descriptively.

Results: At BL, 582/1372 (42%) RA pts, 166/273 (61%) PsA pts, and 157/218 (72%) axSpA pts were employed outside the home. BL demographics were typical of each disease population; mean age of employed pts and pts unemployed due to arthritis/other conditions was similar (Table). Employed pts reported similarly high disease burden at BL across RA, PsA and axSpA (Table); by age, highest absenteeism was in pts aged 35–45 yrs (mean days/month: 3.1 [RA], 2.3 [PsA]) and 25–35 yrs (mean days/month: 2.4 [axSpA]) and presenteeism in pts under 35 yrs (mean days/month: 7.7 [RA], 6.5 [PsA], 7.1 [axSpA]). Compared to employed pts, unemployed pts reported a higher burden on household work and social activities, with highest burden in pts unemployed due to arthritis (Table). Similar improvements were seen in work and household productivity after 1 yr of CZP treatment, regardless of employment status, across all diseases (Table).

Conclusion: RA, PsA and axSpA pts of working age reported comparably high burden of disease on work and household productivity at BL; household burden was greater in disease-disabled pts. CZP treatment leads to comparable improvements in work and household productivity over 1 yr across RA, PsA and axSpA employed and disease-disabled pts. References: 1. Mau W. J Rheumatol 2005;32:721-8; 2. Boonen A. Ann Rheum Dis 2010;69:1123-8; 3. Kavanaugh A. Arthritis Rheum 2009;61(11):1592-600; 4. Kavanaugh A. Ann Rheum Dis 2014;73(2):927-8; 5. Kavanaugh A. Arthritis Rheum 2013;65(S10):S140-1; 6. van der Heijde D. Arthritis Rheum 2013;65(S10):S644-55; 7. Osterhaus J. Arth Res Ther 2009;11(3):R73.

Disclosure: A. F. Kavanaugh, Abbott, Amgen, Bristol-Myers Squibb, Pfizer, Roche, Janssen, UCB Pharma, 2; P. J. Mease, Abbott, AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, UCB Pharma, 2,Abbott, AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Celgene, Covagen, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, UCB Pharma, 5,Abbott, AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Pfizer, UCB Pharma, 8; O. Purcaru, UCB Pharma, 3; D. van der Heijde, AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Celgene, Daiichi, Eli Lilly, Galapagos, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, UCB Pharma, 5,Director of Imaging Rheumatology bv, 3.

To cite this abstract in AMA style:

Kavanaugh AF, Mease PJ, Purcaru O, van der Heijde D. Disease Burden and Impact of Certolizumab Pegol Treatment on Workplace and Household Productivity Across Working Age Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/disease-burden-and-impact-of-certolizumab-pegol-treatment-on-workplace-and-household-productivity-across-working-age-rheumatoid-arthritis-psoriatic-arthritis-and-axial-spondyloarthritis-patients/. Accessed .

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-burden-and-impact-of-certolizumab-pegol-treatment-on-workplace-and-household-productivity-across-working-age-rheumatoid-arthritis-psoriatic-arthritis-and-axial-spondyloarthritis-patients/